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method could be developed in the future as a precise method of
measuring cartilage lesions.
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Purpose: Viscosupplementation by intraarticular injections of hyaluronic
acid (HA) reduces pain and improves function in patients with knee
osteoarthritis (KOA) but the improvement is delayed and occurs usually
6 to 8 weeks after the injections.
ANTI-OX-VS is an innovative viscosupplement made of a high
concentration (20mg/ml) of a 2mDa hyaluronic acid (HA) from non
animal origin, combined with a high concentration of a free radical
scavenger, the sorbitol (40mg/ml). The high afﬁnity between HA and
sorbitol, stabilizes the complex through a very dense network of
hydrogen bonds. The high ability of sorbitol to scavenge and neutralize
reactive oxygen specie (ROS) has been demonstrated to delay the
degradation of the gel due to ROS. We hypothesise that the antioxidant
effect of sorbitol may also play a role to reduce the time to onset of
analgesia.
Objectives: To evaluate the short term pain-relief effect of ANTI-OX-VS
in patients suffering from KOA.
Patients and Methods: Thirteen-week (W) prospective open pilot study.
30 patients suffering from symptomatic KOA (tibiofemoral and/or
patellofemoral, grade 2 to 4) were treated by intra-articular injections
of ANTI-OX-VS. Each patient received 3 intra-articular injections of 2mL
one week apart. Pain and function using the WOMAC scale, walking
pain (WP), patient and physician global assessment (GA) using a 5 point
Likert scale, and percentage of improvement since the ﬁrst injection
were obtained at baseline, W1, W2 and end point (W13). Between the
third injection and W13 patients were asked to complete once a week a
self evaluation questionnaire including WP, WOMAC A, patient GA and
adverse events (AEs).
Primary criteria was the variation of WP between ﬁrst injection and
W3. Secondary criteria: were: Variation of WP, WOMAC A, PGA between
baseline and W1, W2, W3, W8, W13. Variation of WOMAC between
baseline and W13. Percentage of improvement between baseline and
W1, W2, W13.
Results: At baseline mean WP was 2.1 and WOMAC A 8.3. WP
dramatically decreased 1 week after the ﬁrst injection (1.6, p < 0.0003).
At W3 mean WP was 1.5 (p < 0.0003) and decreased again to 1.0 at W13
(p < 0.0001). The mean decrease of WOMAC A at W1, W2, W8 and W13
was −2.1, −2, −2 and −3.9 respectively.
Figure: Mean walking pain assessment by the patient.
Conclusions: This exploratory study suggests a quick and strong pain
relief occurring immediately after the ﬁrst injection of ANTI-OX-
VS, followed by a continuous improvement until the end of follow-
up. Improvement was achieved much faster than that obtained with
other viscosupplements probably because of the presence of high
concentrations of sorbitol through its antioxidant activity. These data
support the need for a large-scale, prospective clinical trial comparing the
safety and long term efﬁcacy of ANTI-OX-VS to regular viscosupplement.
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EVALUATION OF THE EFFECT OF ADDING CORTICOSTEROID TO
VISCOSUPPLEMENTATION: A PROSPECTIVE AND RANDOMIZED STUDY
G.C. Campos. IOT – FMUSP, Campinas, Brazil
Purpose: Clinical studies in the treatment of knee osteoarthritis
have demonstrated that intraarticular injection of hyaluronic acid
provides good results only within 4 weeks after inﬁltration, while
the intraarticular injection of corticosteroids provides good immediate
results, which, however, are lost between 2 and 4 weeks. It is also
known that corticosteroid injection is more effective for knee pain and
function from baseline until the fourth week than viscosupplementation,
time when the results get equivalent for both procedures. After that, up
to 6 months, the injection of hialuronic acid shows better results. The
aim of this study is to assess if we can improve the initial results of
viscosupplementation by the addition of corticosteroids to the procedure,
while keeping the long-term results;
Methods: We evaluated 90 patients with osteoarthritis of the knee,
divided into two groups. Patients in group 1 received knee inﬁltration
of 6ml of Hylan alone. Patients in group 2 received knee inﬁltration of
6ml of Hylan and 1ml (20mg) of hexacetonide Triamcinolone.
We applied the visual analogic scale of pain (VAS) and the
functional questionnaires WOMAC and Lequesne. The questionnaires
were answered before inﬁltration (week zero) and with one, four, twelve
and twenty-four weeks after the puncture (weeks 1, 4, 12 and 24)
Results: The mean age of patients was 61.89 yo. Most were female
(75.5%). The average BMI of patients was 29.75. The radiological
classiﬁcation (Kellgreen and Lawrence) was on average 2.71. Preoperative
scores: WOMAC = 52.47 (SD=17.74); VAS = 69.29 (SD=21.79); Lequesne
= 13.49 (SD=4.24). The groups were statistically analyzed and found to
be parametric.
Week 1:
Group 1 did not show a statistically signiﬁcant improvement compared to
baseline for WOMAC. VAS showed improvement of 13.82% (p =0.007)
and Lequesne improvement of 8.2% (p =0.02)
Group 2 showed improvement in WOMAC (39.02%), VAS (44.08%) and
Lequesne (21.14%), all with a p < 0.01.
Week 4:
Group 1 showed improvement from baseline of 9.3% in WOMAC, 15.04%
in VAS and 13.50% in Lequesne, all p < 0.05;
Group 2 was increased to 43.0% of improvement in Womac, 48.6% in the
VAS and 27.4% in Lequesne, all p < 0.01.
Group 2 is superior to group 1 in all scores at weeks 1 and 4, p < 0.01.
Aroud 33% of the patients reportes adverse effects such as disconfort
(10%) joint effusion (7%) and some degree of pain (22%). The pain lasted
69% longer in group 1 with p < 0.05 (3.26 days against 1.92 days)
Conclusion: We concluded that the addition of 1ml of triancinolone to
the viscosupplementation brings great improvement to the initial results
of the procedure.
